Tag: beigene
January 15, 2019
BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib
BeiGene (NASDAQ:BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the...
December 20, 2018
5 Top Biotech and Pharma Stocks on the TSX Year-to-Date
Which biotech and pharma stocks on the TSX have performed the best in 2018? Here's a look at the top... November 27, 2018
Zymeworks and BeiGene Announce License and Collaboration Agreement
Zymeworks (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and BeiGene (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company... October 24, 2018
BeiGene Announces Acceptance of its New Drug Application in China and Top-Line Pivotal Data for Zanubrutinib
BeiGene (NASDAQ:BGNE;HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of... October 10, 2018
BeiGene Announces National Reimbursement Inclusion of VIDAZA by the State Medical Insurance Administration in China
BeiGene (NASDAQ:BGNE; HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of... August 31, 2018
BeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma in China
BeiGene (NASDAQ:BGNE; HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment... August 9, 2018